Laboratorio Reig Jofre, S.A. · BME:RJF
Laboratorio Reig Jofre — Reig Jofre — Q1 2024 Earnings Presentation
19 slides from Laboratorio Reig Jofre's earnings presentation, May 2024
Slide 1: Financial Results First Quarter 2024
FINANCIAL RESULTS FIRST QUARTER 2024 PHARMA SECTOR
Slide 2: Statement
STATEMENT This presentation does not contain confidential material and may include publicly available market information that has not been independently verified by Reig Jofre. This information is given in summary form and does not purport to be complete. The information contained in this presentati
Slide 3: Table of Contents
TABLE OF CONTENTS Q1 2024 Results → Income statement and balance sheet → RJF stock performance → 2024 OUTLOOK 3
Slide 4: Q1 2024 Results: revenues grow 10% and EBITDA 11%
Q1 2024 RESULTS Reig Jofre’s revenues grow 10% and its EBITDA 11% Sed ut perspiciatis → Sales figures for the first quarter of 2024 increase by 10% compared to the same period in 2023. The medical products division, Speciality Pharmacare, leads this SALES growth, followed by Pharmaceutical Technolog
Slide 5: Q1 2024 Revenues by Business Units
Q1 2024 REVENUES BY BUSINESS UNITS PHARMACEUTICAL SPECIALTY CONSUMER TECHNOLOGIES PHARMACARE HEALTHCARE Antibiotics Osteoarticular OTC / Energy / Stress and sleep / Injectables / Freeze-dried products Dermatology Weight control / Beauty €36.5 M 42% +6% €29.3 M +26% 34% €20.6 M –1% 24% → Growing dema
Slide 6: International Developments
INTERNATIONAL SPAIN Sed ut perspiciatis Rest of EUROPE Sed ut perspiciatis Rest of WORLD DEVELOPMENTS 45% 44% 10% €39.0 M €38.4 M €9.0 M +17% +8% –6% → Spain leads growth with 17% versus the previous year, led by Specialty Pharmacare’ DIRECT SALES €48.9 M sales. European Union +0% 38% → Other Europe
Slide 7: Investment in Biotechnology
INVESTMENT IN BIOTECHNOLOGY → 2018: Syna Therapeutics joint venture Strategic partnership → REIG JOFRE and Leanbio have a 50%-50% joint REIG JOFRE OTHER participation. → Purpose: development of biosimilar products 10% 24% and innovative molecules. REIG JOFRE → In 2023, Syna Therapeutics announced th
Slide 8: Vertical Integration
VERTICAL INTEGRATION → Leanbio’s facility located in Sant Quirze del Vallès, province of Barcelona, of 4,000 square meters. → Production of biotechnology-based active ingredients STRENGTHENS ITS CAPITALIZATION OF and mRNA with GMP Certification. PRESENCE IN THE KNOW-HOW and BIOTECHNOLOGY EXISTING SE
Slide 9: Table of Contents
TABLE OF CONTENTS → Q1 2024 Results Income statement and balance sheet → RJF stock performance → 2024 OUTLOOK 9
Slide 10: Income Statement 1Q 2024
INCOME STATEMENT 1Q 2024 → Turnover increased by 10% with an associated gross margin of 60%. thousands of Euros 31/03/2024 31/03/2023 V% → Personnel costs increase by 9% due to the application in Q1 2024 of the clause for adjusting to the Consumer Price Index Net turnover 86,437 78,644 10% Procureme
Slide 11: Balance Sheet: Assets and Investments
BALANCE SHEET INVESTMENT 1Q 2024 ASSETS AND INVESTMENTS 31/03/2023 €3.3 M thousands of Euros 31/03/2024 31/12/2023 ASSETS INDUSTRIAL Goodwill 27,778 27,985 CAPEX Other intangible assets Property, plant and equipment 61,196 91,154 63,070 91,625 2.8 M Accounting investments equity method 4,317 4,600 F
Slide 12: Balance Sheet: Liabilities and Debt
BALANCE SHEET INVESTMENT 2023 LIABILITIES AND DEBT 31/03/2024 NET FINANCIAL DEBT DEBT / EBITDA Q1 thousands of Euros 31/03/2024 31/12/2023 Q1 2024 €59.9 M 2024 1.7x Q1 1.7x TOTAL EQUITY 206,954 204,254 Subsidies 3,515 3,571 Q1 2023 €55.8 M 2023 Provisions 199 199 Financial liabilities to credit inst
Slide 13: Table of Contents
TABLE OF CONTENTS → Q1 2024 Results → Income statement and balance sheet RJF stock performance → 2024 OUTLOOK 1 3
Slide 14: RJF Stock Performance
RJF STOCK PERFORMANCE YTD APRIL 24 MARKET CAP €198 M RJF (ISIN ES0165359029) €2.49/Share - 30/04/2024 VOLUME CASH PRICE maximum minimum 910 k €2.2 M €2.47/Share €2.70/Share €2.29/Share YTD Shares YTD SHAREHOLDER COMPOSITION Weighted average 10/04/2024 19/01/2024 11 k shares €27 k YTD average daily d
Slide 15: Table of Contents
TABLE OF CONTENTS → Q1 2024 Results → Income statement and balance sheet → RJF stock performance 2024 OUTLOOK 1 5
Slide 16: 2024 Outlook
2024 OUTLOOK OPORTUNITIES RISKS GROWTH IN CYCLOTECH INFLATION → We anticipate a more INJECTABLES AND UNGUEAL RISING WAGE content growth in sales in FREEZE-DRIED THERAPIES COSTS IN SPAIN 2024 than in previous years PRODUCTS FRANCHISE with the aim of increasing profitability in the medium and long ter
Slide 17: Links and Additional Information
LINKS AND ADDITIONAL INFORMATION → RESULTS WEBCAST https://reigjofre.com/en/investors/webcasts/ https://reigjofre.com/en/investors/presentations/ → NEWSLETTER RJF http://www.reigjofre.com/en/news/subscription-center/ → INVESTORS FINANCIAL AND OTHER RELEVANT INFORMATION https://reigjofre.com/en/other
Slide 18: Alternative Performance Measures
REIG JOFRE Alternative performance measures Sed ut perspiciatis The Management utilizes some alternative performance measures in financial, operational, and planning decision-making, as well as to assess the performance of the Group and its subsidiaries. Management considers these alternative perfor
Slide 19: Q1 2024 Thank You
Q1 2024 THANK YOU Gran Capità 10 08970 Sant Joan Despí BARCELONA, SPAIN T. +34 93 480 67 10 www.reigjofre.com Investor Relations investors@reigjofre.com